Lastly, although FGFR3-targeted therapy is performed in clinical practice for patients with MIBC, additional studies are needed to provide FGFR3-targeted therapy to patients with UTUC or NMIBC. The gene discussed is FGFR3; the disease is renal pelvis/ureter urothelial carcinoma.